Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;25(10):1203-9.
doi: 10.1177/0883073809359540. Epub 2010 Feb 22.

SPRED 1 mutations in a neurofibromatosis clinic

Talia M Muram-Zborovski  1 , David A Stevenson, David H Viskochil, David C Dries, Andrew R Wilson, Rong Mao
Affiliations

SPRED 1 mutations in a neurofibromatosis clinic

Talia M Muram-Zborovski et al. J Child Neurol. 2010 Oct.

Abstract

Legius syndrome, caused by SPRED1 mutations, has phenotypic overlap with neurofibromatosis type 1 (NF1) without tumorigenic manifestations. Patients fulfilling the National Institutes of Health (NIH) diagnostic criteria for NF1 were enrolled at the University of Utah NF Clinic, and SPRED1 mutation analysis was performed to identify the frequency of Legius syndrome within an NF1 clinic population. SPRED1 sequencing was performed on 151 individuals with the clinical diagnosis of NF1, and 2 individuals (1.3%) were found to have novel SPRED1 mutations, p.R18X and p.Q194X. The phenotypes for the 2 individuals with SPRED1 mutations included altered pigmentation without tumorigenesis. A specific SPRED1 haplotype allele was identified in 27 individuals. The frequency of SPRED1 mutations in patients meeting diagnostic criteria for NF1 in a hospital-based clinic is 1% to 2%. The likelihood an individual is harboring a SPRED1 mutation increases with age if multiple, nonpigmentary NF1 findings are absent. Legius syndrome patients may benefit from altered medical surveillance.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Fig. 2
Fig. 2
Fig. 3
Fig. 3
See this image and copyright information in PMC

References

    1. Stevenson DA, Swensen J, Viskochil DH. Neurofibromatosis type 1 and other syndromes of the Ras pathway. In: Kaufmann D, editor. Neurofibromatoses. Monographs in Human Genetics. Vol. 16. Basel; Karger: 2008. pp. 32–45.
    1. Brems H, Chmara M, Sahbatou M, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet. 2007;39(9):1120–1126. - PubMed
    1. Pasmant E, Sabbagh A, Hanna N, et al. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet. 2009;46(7):425–430. - PubMed
    1. Spurlock G, Bennett E, Chuzhanova N, et al. SPRED1 mtuations (Legius syndrome): another clinically useful genotype for dissecting the NF1 phenotype. J Med Genet. 2009;46(7):431–437. - PubMed
    1. Neurofibromatosis Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45:575–578. - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts